A study of factors that influence the severity of neonatal narcotic withdrawal
- PMID: 1163362
A study of factors that influence the severity of neonatal narcotic withdrawal
Abstract
1. History is unreliable in assessing maternal drug habit. Morphine was detected in significant amounts in maternal and fetal urine regardless of whether the mother was on a methadone program or whether she denied any use of heroin during the last trimester of pregnancy. 2. Infants born to drug-addicted mothers were, in general, of birthweight normal and appropriate for gestational age (i.e., greater that 10th percentile). The infants born to mothers on a methadone clinic program had a higher birthweight compared to those whose mothers were not on any methadone program. 3. In order of frequency, the signs and symptoms of withdrawal were: central nervous system manifestations-fist sucking, irritability, tremors, sneezing, high-pitch cry, hypertonia; vasomotor in the form of stuffy nose; and gastrointestinal in the form of sweating, diarrhea, vomiting and yawning. Convulsions were not noted. No death occurred. 4. The severity of neonatal narcotic withdrawal did not correlate with the infant's gestational age, APGAR, sex or race; nor with maternal age, parity, duration of heroin addiction or duration of methadone intake. Also, it did not correlate with the total morphine level measured either in infant's or mother's urine or in cord blood. The serum levels of calcium and glucose were normal and identical in either mild or severe withdrawal. 5. The severity of neonatal withdrawal correlated significantly with the methadone dose per day of the mother (in initial, final or average dose). A maternal methadone dose of more than 20 mg per day was associated with a higher incidence of moderate to severe withdrawal in their babies. As a corollary, it was also noted that infants whose mothers were on a high methadone dose (i.e., greater than 20 mg per day) had a greater postnatal weight loss despite a significantly higher birthweight initially, and stayed in the hospital longer. 6. Finally, the modification of the environment to reduce external stimuli to the infant born to a drug-dependent mother, does not prevent or diminish the severity of neonatal narcotic withdrawal. Thus, there is no need to manage these infants in a special nursery.
Similar articles
-
Neonatal addiction: a two-year study. Part I. Clinical and developmental characteristics of infants of mothers on methadone maintenance.Addict Dis. 1975;2(1-2):227-34. Addict Dis. 1975. PMID: 1163366
-
Disposition of methadone and its relationship to severity of withdrawal in the newborn.Addict Dis. 1975;2(1-2):169-78. Addict Dis. 1975. PMID: 1163360
-
[Drug withdrawal in newborns - clinical data of 49 infants with intrauterine drug exposure: what should be done?].Klin Padiatr. 2008 Sep-Oct;220(5):308-15. doi: 10.1055/s-2007-992800. Epub 2008 Feb 7. Klin Padiatr. 2008. PMID: 18260044 German.
-
Neonatal withdrawal syndrome: associated drugs and pharmacologic management.Pharmacotherapy. 1993 May-Jun;13(3):202-11. Pharmacotherapy. 1993. PMID: 8321734 Review.
-
Effects of maternal opiate abuse on the newborn.Fed Proc. 1985 Apr;44(7):2314-7. Fed Proc. 1985. PMID: 3884386 Review.
Cited by
-
L-cysteine ethyl ester prevents and reverses acquired physical dependence on morphine in male Sprague Dawley rats.Front Pharmacol. 2023 Dec 4;14:1303207. doi: 10.3389/fphar.2023.1303207. eCollection 2023. Front Pharmacol. 2023. PMID: 38111383 Free PMC article.
-
Lipophilic analogues of D-cysteine prevent and reverse physical dependence to fentanyl in male rats.Front Pharmacol. 2024 Apr 5;14:1336440. doi: 10.3389/fphar.2023.1336440. eCollection 2023. Front Pharmacol. 2024. PMID: 38645835 Free PMC article.
-
The epigenetic signatures of opioid addiction and physical dependence are prevented by D-cysteine ethyl ester and betaine.Front Pharmacol. 2024 Aug 30;15:1416701. doi: 10.3389/fphar.2024.1416701. eCollection 2024. Front Pharmacol. 2024. PMID: 39281282 Free PMC article.
-
Association of a Simplified Finnegan Neonatal Abstinence Scoring Tool With the Need for Pharmacologic Treatment for Neonatal Abstinence Syndrome.JAMA Netw Open. 2020 Apr 1;3(4):e202275. doi: 10.1001/jamanetworkopen.2020.2275. JAMA Netw Open. 2020. PMID: 32267513 Free PMC article.
-
Non-pharmacological care for opioid withdrawal in newborns.Cochrane Database Syst Rev. 2020 Dec 21;12(12):CD013217. doi: 10.1002/14651858.CD013217.pub2. Cochrane Database Syst Rev. 2020. PMID: 33348423 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials